The search for meaningful prognostic markers in diffuse large B-cell lymphoma

American Journal of Clinical Pathology

Volumn 115, Issue 4, 2001, Pages 481-483

  Hsi, E D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

B CELL LYMPHOMA; CELL PROLIFERATION; DISEASE CLASSIFICATION; EDITORIAL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

GENES, P53; HUMANS; LYMPHOMA, B-CELL; NEPRILYSIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0035057292     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/N87Q-F48C-PU2R-JUX0     Document Type: Editorial

References (29)

1. bcl-2 rearrangements in de novo diffuse large cell lymphoma: Association with distinctive clinical features
2. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma
3. 18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance
4. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases
5. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
6. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor
7. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes
8. A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project
9. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma
10. Clinical relevance of CD10 antigen expression in de novo large B-cell lymphomas
11. Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma
12. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
13. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma
14. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
15. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67
16. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial
17. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time
18. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study
19. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
20. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations
21. MDM2 over-expression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas
22. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas
23. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
24. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases
25. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
26. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma
27. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
28. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling
29. Tissue microarrays for high-throughput molecular profiling of tumor specimens